Overview
Malignant white blood cell disorders encompass a spectrum of hematologic malignancies, including Hodgkin’s Lymphoma (HL), Non-Hodgkin’s Lymphoma (NHL), Multiple Myeloma (MM), Chronic Lymphocytic Leukemia (CLL), and Acute Myeloid Leukemia (AML). These conditions vary widely in their aggressiveness and treatment requirements, ranging from indolent diseases manageable with low-intensity treatments to highly aggressive forms necessitating intensive therapies [PMID:28887271]. The management of these malignancies often involves high-dose chemotherapy followed by hematopoietic stem cell transplantation (HSCT), a procedure that can be curative but is associated with significant morbidity and prolonged hospitalization periods of 3-4 weeks [PMID:38280483]. Palliative care plays a crucial role in improving the quality of life (QOL) for patients facing these serious illnesses, addressing not only physical symptoms but also psychological, social, and spiritual needs [PMID:32066301]. Despite its recognized benefits, the integration of palliative care remains suboptimal, often perceived as terminal care rather than a supportive adjunct to active treatment [PMID:32321483]. This guideline aims to provide a comprehensive framework for clinicians managing patients with malignant white blood cell disorders, emphasizing the importance of early and integrated palliative care approaches.
Epidemiology
The epidemiology of hematologic malignancies reflects diverse global patterns and increasing incidence trends. Hodgkin’s Lymphoma (HL) has seen a notable rise, with cases increasing by 38.6% between 1990 and 2017, affecting approximately 1.4 million individuals [PMID:36753254]. Non-Hodgkin’s Lymphoma (NHL) and Multiple Myeloma (MM) represent larger burdens, impacting around 7.0 million and 2.3 million people, respectively [PMID:36753254]. Chronic Lymphocytic Leukemia (CLL) and Acute Myeloid Leukemia (AML) also exhibit increasing incidence rates across most countries, highlighting the growing public health challenge these diseases pose [PMID:36753254]. Disparities in symptom screening uptake among Adolescents and Young Adults (AYA) cancer patients further complicate care, suggesting that current programs may not adequately reach or serve this population equitably [PMID:34738747]. Understanding these epidemiological trends is crucial for tailoring public health strategies and improving early detection and intervention efforts.
Clinical Presentation
Patients with malignant white blood cell disorders experience a multifaceted symptom burden that significantly impacts their quality of life (QOL). During hematopoietic stem cell transplantation (HSCT), a critical phase in the management of hematologic malignancies, 50-70% of patients report moderate to severe symptoms such as nausea, vomiting, fatigue, diarrhea, mucositis, and pain [PMID:38280483]. These symptoms not only diminish QOL but also affect mood and overall psychological well-being. Adolescents and Young Adults (AYA) cancer patients face particularly substantial psychological, spiritual, social, and physical symptoms, mirroring those seen in patients with metastatic solid tumors [PMID:32321483]. The Symptom Screening in Pediatrics Tool (SSPedi) further underscores the frequent reporting of bothersome symptoms by inpatient children with cancer and HSCT recipients, with many experiencing symptoms rated as 'a lot' or 'extremely bothered' [PMID:29573197]. Effective symptom management strategies are essential to mitigate these impacts and improve patient outcomes. The development and validation of tools like the Family Symptom Inventory (FSI) highlight the importance of addressing both physical and psychological symptoms in pediatric patients undergoing hematology/oncology treatment [PMID:25692615]. Clinicians must adopt a holistic approach to symptom assessment and management, integrating early palliative care interventions to enhance overall patient care.
Differential Diagnosis
Differentiating malignant white blood cell disorders from other hematologic conditions can be challenging due to overlapping clinical presentations. Hematologic specialists often resist integrating palliative care early in the treatment trajectory due to concerns that it might be perceived as terminal care rather than supportive care, potentially conflicting with ongoing active treatments [PMID:32321483]. This resistance underscores the need for clearer communication about the role of palliative care in enhancing quality of life and symptom management throughout the disease course, not just at the end stages. Clinicians must navigate these perceptions carefully, emphasizing the complementary nature of palliative care in conjunction with curative therapies. Understanding the specific clinical features and laboratory findings unique to each malignancy (e.g., specific chromosomal abnormalities in AML, immunophenotypic markers in lymphomas) is crucial for accurate diagnosis and tailored management strategies.
Management
The management of malignant white blood cell disorders requires a multidisciplinary approach, integrating aggressive treatments with supportive and palliative care to optimize patient outcomes. Hematopoietic stem cell transplantation (HSCT) remains a cornerstone for potentially curative treatment in many hematologic malignancies, though it is associated with significant morbidity and prolonged hospitalization [PMID:38280483]. Early integration of palliative care during HSCT has shown promising results in improving symptom management and QOL, with multi-site randomized trials aiming to further validate these benefits across diverse care settings [PMID:38280483]. For aggressive diseases like Acute Myeloid Leukemia (AML), rapid diagnosis and specialized treatment are critical, yet survival rates remain challenging, with only about one in four patients surviving five years or more despite recent advancements [PMID:36753254]. Systematizing care through structured care lines (CL) ensures timely and comprehensive support, facilitating clinical decision-making and patient follow-up across healthcare services [PMID:36753254]. Universal symptom screening programs, such as the Edmonton Symptom Assessment Scale (ESAS), are essential for identifying and addressing symptoms in Adolescents and Young Adults (AYA) cancer patients, potentially reducing disparities and enhancing supportive care [PMID:34738747]. Evidence from solid tumors supports the efficacy of early palliative care in improving QOL and reducing symptom intensity, advocating for similar integration in hematologic malignancies to manage their high symptom burdens [PMID:32321483]. Clinicians should prioritize symptom screening tools like SSPedi and FSI to tailor interventions effectively, ensuring holistic care that addresses physical, psychological, and social dimensions.
Prognosis & Follow-up
The prognosis for malignant white blood cell disorders varies significantly based on the specific malignancy and patient characteristics. Acute Myeloid Leukemia (AML), for instance, continues to pose significant challenges despite advancements, with a five-year survival rate of only about 25% [PMID:36753254]. Patients often experience more frequent hospitalizations and aggressive treatments in their final stages compared to those with solid tumors, highlighting the need for early palliative care interventions to mitigate these burdens [PMID:32321483]. Factors such as age and gender influence symptom severity and overall burden, guiding targeted supportive care interventions [PMID:29573197]. Palliative care should encompass a comprehensive approach addressing physical, psychological, spiritual, legal, and cultural aspects to support patients with serious hematologic illnesses throughout their disease trajectory [PMID:28887271]. Chronic graft-versus-host disease (cGVHD), a common complication post-HSCT, extends recovery periods and significantly impacts quality of life and spiritual well-being, necessitating holistic care strategies [PMID:20552925]. Regular psychosocial assessments, such as those using the Family Symptom Inventory (FSI), can enhance overall care and potentially influence long-term outcomes for pediatric patients [PMID:25692615]. Clinicians must remain vigilant in monitoring and addressing evolving needs, ensuring that palliative care is seamlessly integrated into follow-up strategies to optimize patient well-being.
Special Populations
Special attention is required for specific patient populations, including Adolescents and Young Adults (AYA) and caregivers, given their unique challenges and needs. AYA cancer patients often face significant psychological distress and may experience disparities in symptom screening uptake, underscoring the necessity for tailored supportive care interventions [PMID:34738747]. Caregivers supporting patients through HSCT and subsequent treatments endure substantial emotional and personal burdens, leading to long-term psychological impacts on both caregivers and patients [PMID:38280483]. Survivors of HSCT who develop chronic graft-versus-host disease (cGVHD) may experience poorer spiritual well-being and functional limitations compared to other cancer survivors, emphasizing the need for comprehensive support addressing these specific issues [PMID:20552925]. Addressing the distinct physical, psychological, and functional needs of hematologic malignancy patients compared to those with solid tumors is crucial, as highlighted by comparative studies [PMID:28887271]. Tailored palliative care approaches that consider these unique challenges can significantly enhance the overall well-being and quality of life for these vulnerable populations.
Key Recommendations
These recommendations aim to optimize patient care by addressing the multifaceted needs of individuals with malignant white blood cell disorders, ensuring a balanced approach that integrates aggressive treatments with supportive and palliative care strategies.
References
1 Yang D, Newcomb R, Kavanaugh AR, Khalil D, Greer JA, Chen YB et al.. Protocol for multi-site randomized trial of inpatient palliative care for patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. Contemporary clinical trials 2024. link 2 Rocha MCDS, Azevedo VD, Santos MFLD, Soares RDA, Santos VEP, Azevedo IC. Elements for assistance to patients with hematological malignancies to propose care lines: a scoping review. Revista brasileira de enfermagem 2023. link 3 Gupta S, Sutradhar R, Li Q, Coburn N. The effectiveness of a provincial symptom assessment program in reaching adolescents and young adults with cancer: A population-based cohort study. Cancer medicine 2021. link 4 Tanzi S, Luminari S, Cavuto S, Turola E, Ghirotto L, Costantini M. Early palliative care versus standard care in haematologic cancer patients at their last active treatment: study protocol of a feasibility trial. BMC palliative care 2020. link 5 Johnston DL, Hyslop S, Tomlinson D, Baggott C, Gibson P, Orsey A et al.. Describing symptoms using the Symptom Screening in Pediatrics Tool in hospitalized children with cancer and hematopoietic stem cell transplant recipients. Cancer medicine 2018. link 6 Hochman MJ, Yu Y, Wolf SP, Samsa GP, Kamal AH, LeBlanc TW. Comparing the Palliative Care Needs of Patients With Hematologic and Solid Malignancies. Journal of pain and symptom management 2018. link 7 Harris BA, Berger AM, Mitchell SA, Steinberg SM, Baker KL, Handel DL et al.. Spiritual well-being in long-term survivors with chronic graft-versus-host disease after hematopoietic stem cell transplantation. The journal of supportive oncology 2010. link 8 Gatta B, LeBlanc TW. Palliative care in hematologic malignancies: a multidisciplinary approach. Expert review of hematology 2020. link 9 Karlson CW, Haynes S, Faith MA, Elkin TD, Smith ML, Megason G. Development of the family symptom inventory: a psychosocial screener for children with hematology/oncology conditions. Journal of pediatric hematology/oncology 2015. link 10 McGrath P. End-of-life care in hematology: update from Australia. Journal of social work in end-of-life & palliative care 2013. link 11 Kristjanson LJ, White K. Clinical support for families in the palliative care phase of hematologic or oncologic illness. Hematology/oncology clinics of North America 2002. link00023-0)